Labiotech.eu

News and Trends 29 Mar 2019

Liquid Biopsy for Lung Cancer Gets €46M Boost

Inivata has raised a €46M (£40M) Series B round that will further advance the commercialization of the company’s blood test for lung cancer as well as the development of new tests. Investors include Woodford patient Capital Trust, IP Group, Cambridge Innovation Capital, Johnson & Johnson Innovation and RT Ventures. Based in both the US and […]

March 29, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Mar 2019

French Diabetes Company Cellnovo Goes into Administration

Paris-based Cellnovo has cut down on staff as well as stopped manufacturing and selling its diabetes management system as the company found itself unable to scale up. Until this week, Cellnovo was selling a diabetes management system consisting of a small insulin pump that was controlled via smartphone. Hundreds of diabetics using this technology have […]

March 29, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Galapagos Gilead filgotinib rheumatoid arthritis

News and Trends 29 Mar 2019

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years after its foundation, Galapagos is finally approaching the finish line. Yesterday, the company has shared positive data from two clinical trials that together enrolled […]

March 29, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

som biotech huntingtons disease repurpose amyloidosis

Startup Scout 29 Mar 2019

This Biotech Repurposes Drugs to Fight Huntington’s Disease

Barcelona-based SOM Biotech is developing treatments for incurable diseases such as Huntington’s disease with drugs that are already on the market for other diseases. Mission: To repurpose commercially available drugs for the treatment of neurological diseases lacking effective treatments. Using existing drugs to treat these rare, orphan diseases lets the company get the treatments to […]

March 29, 2019 - 4 minutesmins - By Jonathan Smith

orchard therapeutics cell therapy stem cell rare disease

News and Trends 28 Mar 2019

Gene Therapy Exceeds Expectations in Treating Children’s Neurological Disease

A gene therapy developed by the UK company Orchard Therapeutics has greatly improved the motor symptoms of children with an incurable neurological disease. The 20 children in the phase II trial suffered from metachromatic leukodystrophy, a rare genetic disease caused by the mutation of a protein that breaks down sulfur-containing molecules in cells. This leads […]

March 28, 2019 - 3 minutesmins - By Jonathan Smith

polyneuron anti mag peripheral neuropathy autoimmune disease nerve

News and Trends 28 Mar 2019

Swiss Biotech Raises €20M to Develop Decoy Drugs in Autoimmune Disease

The biotech Polyneuron has raised a Series A round of €20.1M (CHF 22.5M) to start human testing with a treatment for a rare autoimmune disease. Based in Basel, Polyneuron is developing drugs to treat anti-MAG peripheral neuropathy. This debilitating disease is caused by the immune system producing autoantibodies that attack nerve support cells, which stops […]

March 28, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Mar 2019

Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M

After some big failures from its top competitors earlier this year, French company Genfit has done an IPO to prepare the launch of its drug for NASH, a chronic liver disease for which there is currently no treatment. Today, Genfit has started trading on Nasdaq. Together with issuing new shares in its existing Euronext Paris […]

March 27, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Heptares AstraZeneka AZD4635 checkpoint inhibitor

News and Trends 27 Mar 2019

Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy

The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop treatments for tumors that don’t respond to checkpoint inhibitor drugs. In the last five years, checkpoint inhibitor drugs have become a potentially life-saving option for people that don’t respond to traditional cancer treatments. These antibody drugs have shown promise in […]

March 27, 2019 - 2 minutesmins - By Jonathan Smith

bioarctic alzheimers disease plaques amyloid beta neurons Edited

More News! 25 Mar 2019

Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug

The failure of Biogen’s Alzheimer’s disease drug in a phase III trial last week caused BioArctic’s stock price to plummet by 35% on Nasdaq Stockholm. The Swedish company has just begun a phase III trial of its own Alzheimer’s treatment. Last week, Biogen and its pharma collaborator Eisai discontinued the phase III development of an […]

March 25, 2019 - 2 minutesmins - By Jonathan Smith

In Depth 25 Mar 2019

Where Does Brexit Leave European Biotech?

In the next couple of months, the UK will officially exit the EU, in a move that is popularly known as Brexit. With this date fast approaching, companies, organizations and individuals all over the world have speculated about how Brexit might impact them. According to the UK Prime Minister, Theresa May, at the launch of […]

March 25, 2019 - 9 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 22 Mar 2019

Danish Startup Gets €5.5M to Produce Hard-to-Make Chemicals Through Fermentation

CysBio is developing a fermentation technology to produce valuable chemicals that were previously too difficult or expensive to make. Founded just at the beginning of this year, CysBio is now receiving its first funding. This seed investment comes from the Chinese chemical company Zhejiang NHU, which has also established a partnership to commercialize some of […]

March 22, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Mar 2019

Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery

In a deal with €22M paid upfront and undisclosed “substantial milestones and royalties,” Exscientia will use its artificial intelligence technology to help Celgene speed up the discovery of drug candidates for cancer and autoimmune diseases. “It is the largest AI drug discovery deal done in the industry to date,” said Andrew Hopkins, CEO of Oxford-based […]

March 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liquid Biopsy for Lung Cancer Gets €46M Boost

French Diabetes Company Cellnovo Goes into Administration

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

This Biotech Repurposes Drugs to Fight Huntington’s Disease

Gene Therapy Exceeds Expectations in Treating Children’s Neurological Disease

Swiss Biotech Raises €20M to Develop Decoy Drugs in Autoimmune Disease

Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M

Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy

Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug

Where Does Brexit Leave European Biotech?

Danish Startup Gets €5.5M to Produce Hard-to-Make Chemicals Through Fermentation

Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!